Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $47.91 USD
Change Today +0.86 / 1.83%
Volume 3.4M
ZTS On Other Exchanges
Symbol
Exchange
Berlin
As of 8:04 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

zoetis inc (ZTS) Key Developments

Zoetis Inc. Appoints Paul M. Bisaro to Board of Directors, Effective May 1, 2015

Zoetis Inc. announced that its Board of Directors has appointed Paul M. Bisaro, Executive Chairman of Actavis plc, to the company’s Board of Directors. Mr. Bisaro’s term will begin immediately following the company’s 2015 Annual Meeting of Shareholders, which is scheduled for May 1, 2015. With the addition of Mr. Bisaro, the Zoetis Board will expand to 11 directors, and he will serve on the Compensation Committee. He previously served as President, CEO and Chairman of the Board of Actavis. Prior to joining Actavis, he was President and Chief Operating Officer of Barr Pharmaceuticals Inc. He also served as General Counsel at Barr and held various additional roles, including Senior Vice President of Strategic Business Development. Prior to joining Barr, Mr. Bisaro was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds. He also served as a Senior Consultant with Arthur Andersen & Co.

Zoetis Inc. Presents at Jefferies 2015 Animal Health Summit, Mar-26-2015 09:30 AM

Zoetis Inc. Presents at Jefferies 2015 Animal Health Summit, Mar-26-2015 09:30 AM. Venue: New York, New York, United States. Speakers: Juan Ramón Alaix, Chief Executive Officer and Director.

Zoetis Inc. Declares Dividend for the Second Quarter of 2015, Payable on June 2, 2015

The Board of Directors of Zoetis Inc. has declared a second quarter 2015 dividend payable to holders of the company's common stock of $0.083 per share. The dividend is to be paid on Tuesday, June 2, 2015, to holders of record on April 9, 2015.

Zoetis Inc. Presents at Barclays Global Healthcare Conference, Mar-12-2015 11:15 AM

Zoetis Inc. Presents at Barclays Global Healthcare Conference, Mar-12-2015 11:15 AM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Juan Ramón Alaix, Chief Executive Officer and Director.

Zoetis Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full year Ended December 31, 2014; Revises Earnings Guidance for 2015

Zoetis Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenue of $1,320 million against $1,254 million a year ago. Income before provision for taxes on income was $155 million against $126 million a year ago. Net income attributable to the company was $126 million against $105 million a year ago. Diluted earnings per share were $0.25 against $0.21 a year ago. Non-GAAP income before provision for taxes on income was $249 million against $252 million a year ago. Non-GAAP net income attributable to the company was $203 million against $180 million a year ago. Non-GAAP diluted earnings per common share attributable to the company were $0.40 against $0.36 a year ago. For the year, the company reported revenue of $4,785 million against $4,561 million a year ago. Income before provision for taxes on income was $820 million against $690 million a year ago. Net income attributable to the company was $583 million against $504 million a year ago. Diluted earnings per share were $1.16 against $1.01 a year ago. Non-GAAP income before provision for taxes on income was $1,084 million against $1,000 million a year ago. Non-GAAP net income attributable to the company was $790 million against $709 million a year ago. Non-GAAP diluted earnings per common share attributable to the company were $1.57 against $1.42 a year ago. For 2015, the company expects revenue to be in the range of $4,800 million to $4,900 million against $4,850 million to $4,950 million as previously expected. The company expects operational growth to be in the range of 6.5% to 8.5%. Effective tax rate on adjusted income approximately 29%. The company expects adjusted diluted EPS to be in the range of $1.61 to $1.68 and adjusted net income to be in the range of $810 million to $845 million. The company expects reported diluted EPS to be in the range of $1.32 to $1.39 against $1.36 to $1.43 as previously expected. The company expects reported net income attributable to the company to be in the range of $665 million to $700 million. Adjusted interest expense and other (income)/deductions of approximately $110 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZTS:US $47.91 USD +0.86

ZTS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abaxis Inc $63.62 USD +0.31
CEVA Inc $21.63 USD -0.27
IDEXX Laboratories Inc $164.05 USD +4.65
Vetoquinol SA €35.56 EUR +0.01
Virbac SA €236.85 EUR +2.85
View Industry Companies
 

Industry Analysis

ZTS

Industry Average

Valuation ZTS Industry Range
Price/Earnings 40.5x
Price/Sales 4.9x
Price/Book 18.0x
Price/Cash Flow 36.6x
TEV/Sales 4.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOETIS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.